Stockhead | Interview with Howie McKibbon

/in , , , /by

Botanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.

Here’s an excerpt:

“It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth as a company. We’ll continue to focus on building Botanix to become the world’s largest and most innovative dermatology company.”

Sharecafe | Interview with Howie McKibbon

/in , , /by

Botanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress.

Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a digital marketing campaign that’s driving awareness and converting online interest into prescriptions.

Sharecafe | Interview with Matt Callahan

/in , , /by

Botanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™.

Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.

Botanix included in ASX 300 Index

/in , , , /by

Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance.

The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.

To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually to reflect changes in market capitalization and liquidity.

Click here to see the ASX announcement

Botanix Releases Quarterly Reports

/in , , , /by

Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.

Botanix Featured in AFR

/in , /by

The Australian Financial Review has featured Botanix as an ASX favourite.

In an article profiling stock picks by Liam Donohue from Lennox Capital, he assessed the market opportunity for Sofdra™:

‘…current treatments have been more invasive (such as targeted Botox injections) and typically less effective.

‘So, with many of the more binary risks out of the way for Botanix, we think the opportunity in front of the company is immense. That is especially the case when you couple this with management’s history of commercialising pharma products in the US.’

Click here to read the full article.

The West Australian: ‘Botanix ships first batch of sweat-stopper gel’

/in , , /by

Botanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso.

Read article

First Sofdra™ prescriptions as commercialization ramps up

/in , , , /by

First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.

View release.

Botanix presentation at Bell Potter Healthcare Conference

/in , , , /by

Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.

View ASX release.